Holen Sie sich die Stockscreener-App
17.45
2.24%
-0.40
Handel nachbörslich:
17.45
Schlusskurs vom Vortag:
$17.85
Offen:
$17.84
24-Stunden-Volumen:
106.07K
Relative Volume:
0.75
Marktkapitalisierung:
$663.57M
Einnahmen:
$239.40M
Nettoeinkommen (Verlust:
$104.44M
KGV:
-6.7636
EPS:
-2.58
Netto-Cashflow:
$-18.50M
1W Leistung:
-12.27%
1M Leistung:
+0.06%
6M Leistung:
+16.41%
1J Leistung:
+7.58%
1-Tages-Spanne:
$17.40
$18.18
1-Wochen-Bereich:
$17.40
$20.49
52-Wochen-Spanne:
$10.75
$20.49
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Firmenname
Entrada Therapeutics Inc
Sektor
Branche
Telefon
857-305-1825
Adresse
ONE DESIGN CENTER PLACE, BOSTON
Vergleichen Sie TRDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| TRDA | 17.45 | 663.57M | 239.40M | 104.44M | -18.50M | -2.58 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-03 | Eingeleitet | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Aktie (TRDA) Neueste Nachrichten
Los Angeles Capital Management LLC Purchases Shares of 33,932 Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Insider Sale at Entrada Therapeutics Inc (TRDA) by President of Research & Development - GuruFocus.com
Entrada Therapeutics stock hits 52-week high at $20.28 By Investing.com - Investing.com UK
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates - MSN
HC Wainwright Issues Positive Forecast for Entrada Therapeutics (NASDAQ:TRDA) Stock Price - Defense World
HC Wainwright Analysts Boost Earnings Estimates for TRDA - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World
Entrada Therapeutics president sells shares worth $339,280 By Investing.com - Investing.com Australia
Equities Analysts Issue Forecasts for TRDA FY2024 Earnings - MarketBeat
HC Wainwright Has Positive Outlook of TRDA FY2024 Earnings - MarketBeat
Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock - Benzinga
Oppenheimer Issues Positive Forecast for Entrada Therapeutics (NASDAQ:TRDA) Stock Price - MarketBeat
Entrada Therapeutics stock target increased on positive trial data By Investing.com - Investing.com UK
Entrada Therapeutics (NASDAQ:TRDA) Price Target Raised to $20.00 - MarketBeat
Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Entrada Therapeutics’ Q3 2024 Financial Highlights - TipRanks
Entrada Therapeutics (NASDAQ:TRDA) Hits New 12-Month HighHere's What Happened - MarketBeat
Entrada Therapeutics stock hits 52-week high at $18.22 By Investing.com - Investing.com UK
Entrada Therapeutics : Corporate Presentation - Marketscreener.com
Entrada Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
Here's Why Momentum in Entrada Therapeutics (TRDA) Should Keep going - MSN
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Short Interest Down 19.1% in October - MarketBeat
Short Interest in Entrada Therapeutics, Inc. (NASDAQ:TRDA) Declines By 19.1% - Defense World
Here's What Could Help Entrada Therapeutics (TRDA) Maintain Its Recent Price Strength - MSN
Entrada Therapeutics president sells $10,800 in stock By Investing.com - Investing.com Australia
Natarajan Sethuraman Sells 600 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock - MarketBeat
There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding - Simply Wall St
Oppenheimer Initiates Coverage of Entrada Therapeutics (TRDA) with Outperform Recommendation - MSN
(TRDA) Trading Report - Stock Traders Daily
The Manufacturers Life Insurance Company Purchases 2,146 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Renaissance Technologies LLC Invests $636,000 in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics advances Duchenne treatment trials - Investing.com
Entrada Therapeutics advances Duchenne treatment trials By Investing.com - Investing.com UK
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society - The Manila Times
HRMY: 3 Small-Cap Biotech Stocks to Buy for Major Upside - StockNews.com
(TRDA) Trading Advice - Stock Traders Daily
Morguard Un (MRT-UN-T) QuotePress Release - The Globe and Mail
Pompe Disease Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Market Dynamics, MOA, ROA by DelveInsight | M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas - The Globe and Mail
Entrada Therapeutics COO sells shares worth over $13,000 - Investing.com India
Entrada Therapeutics COO sells shares worth over $13,000 By Investing.com - Investing.com Australia
Insider Sale: President & COO Nathan Dowden Sells Shares of Entr - GuruFocus.com
Entrada Therapeutics (NASDAQ:TRDA) Trading 4.8% Higher - MarketBeat
U.S. Gold Corp (USAU-Q) QuotePress Release - The Globe and Mail
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development - Markets Insider
Entrada Therapeutics appoints new President of R&D - Investing.com
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
Finanzdaten der Entrada Therapeutics Inc-Aktie (TRDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):